Ascend Wellness Holdings (AAWH) Other Non-Current Liabilities (2022 - 2026)
Ascend Wellness Holdings (AAWH) posted quarterly Other Non-Current Liabilities of $224.3 million for Q1 2026, up 29.41% year-over-year from $173.3 million in Q1 2025, and up 6.58% quarter-over-quarter from $210.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Ascend Wellness Holdings' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $224.3 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 29.41% year-over-year to $224.3 million; the TTM figure through Mar 2026 stood at $224.3 million (up 29.41% YoY), while the FY2025 annual figure was $210.5 million, up 32.46% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $224.3 million, up from $210.5 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $224.3 million in Q1 2026, with the low at $1.8 million in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $94.2 million (2023), against an average of $93.1 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities jumped 719.98% in 2024, then slumped 98.68% in 2025.
- Ascend Wellness Holdings' Other Non-Current Liabilities stood at $15.1 million in 2022, then surged by 494.29% to $89.6 million in 2023, then soared by 77.34% to $158.9 million in 2024, then surged by 32.46% to $210.5 million in 2025, then climbed by 6.58% to $224.3 million in 2026.
- Business Quant data shows AAWH's Other Non-Current Liabilities at $224.3 million in Q1 2026, $210.5 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Ascend Wellness Holdings | 83.23 Mn | 16.23 Mn | 45.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 219.57 Mn |
| Mar 31, 2026 | 224.31 Mn |
| Dec 31, 2025 | 210.46 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 184.46 Mn |
| Mar 31, 2025 | 173.34 Mn |
| Dec 31, 2024 | 158.89 Mn |
| Sep 30, 2024 | 136.69 Mn |
| Jun 30, 2024 | 122.47 Mn |
| Mar 31, 2024 | 98.72 Mn |
| Dec 31, 2023 | 89.60 Mn |
| Sep 30, 2023 | 16.67 Mn |
| Jun 30, 2023 | 16.07 Mn |
| Mar 31, 2023 | 15.57 Mn |
| Dec 31, 2022 | 15.08 Mn |
| Sep 30, 2022 | 14.84 Mn |
| Jun 30, 2022 | 10.00 Mn |